retatrutide ada 2025 results Highlights: A New Era for GLP-1 Therapies in Obesity and Diabetes Retatrutide Phase 3: 60% Achieved

Meaningful body composition changes become visible during this phase

Weight loss slows

However, little is known of the mechanisms underlying glucose-induced autophagy in renal tubular epithelial cells

Study period 1/1/2017 to 7/1/2025 Study population: inclusion Patients with A GLP-1 prescription for at least 90 days At least five pounds of weight loss while on the GLP-1 A weight reading between 30 days prior through 3 days after starting the GLP-1 A weight reading within 30 days of stopping the GLP-1 At least one weight reading 1 to 24 months following end of the GLP-1 Study population: exclusion Thyroid conditions (ever): ICD-10-CM E03*or E05* Eating disorders (ever): ICD-10-CM F50* Pregnancy within a year before GLP-1 start through GLP-1 stop Censoring Other weight loss medication or restart of GLP-1 Amputation Bariatric surgery Pregnancy that started in period after GLP-1 was stopped Outcomes Percent of weight change relative to initial weight loss after end of GLP-1 treatment GLP-1 A medication with a simple generic of semaglutide, liraglutide, or tirzepatide

What states are considering legislation related to coverage of weight-loss drugs

So we think of it really as a disease in which we have a treatment for it that we can hopefully put the individual control it and hopefully put them in remission but currently it only works if you take the medication